US09061G1013
© PR Newswire
12.01.2026
BMRN
LISTED
NASDAQ
BioMarin Appoints Arpit Davé Chief Digital and Information Officer
News Preview
Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical IndustrySAN RAFAEL, Calif., Jan. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has appointed Arpit Davé as Executive...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2026
BMRN
LISTED
NASDAQ
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
News Preview
SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 44th Annual J.P. Morgan Conference on Monday, January 12, 2026, at 11:15 am PT / 2:15 pm ET, in San Francisco, California. The Company plans to ann...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2025
BMRN
LISTED
NASDAQ
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
News Preview
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in Revenue Over Past Four QuartersProvides Opportunity to Expand Access to Galafold and Pombiliti + Opfolda to Patients in New Markets Across BioM...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
11.11.2025
BMRN
LISTED
NASDAQ
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
News Preview
SAN RAFAEL, Calif., Nov. 11, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England in London....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
29.10.2025
BMRN
LISTED
NASDAQ
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
News Preview
Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet alone
FDA PDUFA target action date of Feb. 28, 2026...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
BMRN
LISTED
NASDAQ
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
News Preview
Raises Full-year 2025 Total Revenues Guidance at the Midpoint; Reaffirms VOXZOGO Full-year Outlook
2025 Year-to-date Total Revenues Increased 11% Y/Y Led by More Than 20% Revenue Growth for PALYNZIQ and VOXZOGO
BioMarin Focuses Commercial Portfolio; Pursuing Options to Divest ROCTAVIAN...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
BMRN
LISTED
NASDAQ
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
News Preview
SAN RAFAEL, Calif., Oct. 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, October 27, 2025, at 4:30 p.m. ET to discuss third quarter 2025 financial result...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
BMRN
LISTED
NASDAQ
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
News Preview
Children who received VOXZOGO showed anatomical improvements in spinal morphology
VOXZOGO continued to significantly improve growth in children who received the medicine after puberty onset
SAN RAFAEL, Calif., Sept. 8, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from 14 studies were presented at the...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
BMRN
LISTED
NASDAQ
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
News Preview
New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission to global health authorities on track for second half of 2025
SAN RAFAEL, Calif., Sept. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new dat...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2025
BMRN
LISTED
NASDAQ
BioMarin to Participate in Upcoming Investor Conferences
News Preview
Cantor Global Healthcare Conference, September 3 at 8:00 am ESTWells Fargo Healthcare Conference, September 4 at 8:45 am ESTMorgan Stanley Global Healthcare Conference, September 9 at 11:30 am ESTSAN RAFAEL, Calif., Aug. 27, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming i...
Themefolio
Profiler
Peergroup
© PR Newswire
01.08.2025
BMRN
LISTED
NASDAQ
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
News Preview
SAN RAFAEL, Calif., Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T. Clark to the company's Board of Directors, effective today, August 1, 2025.
Mr. Clark serv...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
BMRN
LISTED
NASDAQ
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
News Preview
SAN RAFAEL, Calif., July 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 4, 2025, at 4:30 p.m. ET to discuss second quarter 2025 financial results and provide a general business up...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
01.07.2025
BMRN
LISTED
NASDAQ
BioMarin Announces Completion of Acquisition of Inozyme
News Preview
SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies por...
Themefolio
Profiler
Peergroup
© PR Newswire
24.06.2025
BMRN
LISTED
NASDAQ
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
News Preview
Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis
No new safety signals observed
SAN RAFAEL, Calif., June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data underscoring the long...
Themefolio
Profiler
Peergroup
© PR Newswire
12.05.2025
BMRN
LISTED
NASDAQ
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
News Preview
New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function
Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of com...
Themefolio
Profiler
Peergroup
© PR Newswire
17.04.2025
BMRN
LISTED
NASDAQ
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
News Preview
SAN RAFAEL, Calif., April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business upd...
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2025
BMRN
LISTED
NASDAQ
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
News Preview
Company plans to submit for regulatory approval later this year
SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe level...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
BMRN
LISTED
NASDAQ
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clini
News Preview
New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality of life for adults with phenylketonuria
SAN RAFAEL, Calif., March 20, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
BMRN
LISTED
NASDAQ
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
News Preview
SAN RAFAEL, Calif., Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA....
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
BMRN
LISTED
NASDAQ
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
News Preview
SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the company's Board of Directors, effective Feb. 24, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
05.02.2025
BMRN
LISTED
NASDAQ
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
News Preview
SAN RAFAEL, Calif., Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
BMRN
LISTED
NASDAQ
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
News Preview
SAN RAFAEL, Calif., Jan. 13, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany. The patent covers long-acting variants of C-Type Natriuret...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
BMRN
LISTED
NASDAQ
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
News Preview
SAN RAFAEL, Calif., Jan. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 43rd Annual J.P. Morgan Conference on Monday, January 13, 2024, at 9:00 am PT / 12:00 pm ET, in San Francisco, California....
Themefolio
Profiler
Peergroup
© PR Newswire
16.11.2024
BMRN
LISTED
NASDAQ
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
News Preview
SAN RAFAEL, Calif., Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia. These results, as well as data from the investigational research program for VOXZOGO in hypochondroplasia,...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
BMRN
LISTED
NASDAQ
BioMarin to Participate in Three Upcoming Investor Conferences
News Preview
UBS Global Healthcare Conference on November 12 at 11:00 am PSTJefferies London Healthcare Conference on November 19 at 9:00 am GMT7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PSTSAN RAFAEL, Calif., Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at th...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
BMRN
LISTED
NASDAQ
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
News Preview
Third Quarter 2024 Total Revenues of $746 million (+28% Y/Y and +32% at Constant Currency Y/Y); Year-to-date 2024 Total Revenues of $2.11 billion (+19% Y/Y and +23% at Constant Currency Y/Y)
During the Quarter, Strong Demand Drove 54% Y/Y Revenue Growth for VOXZOGO®
During the Quarter, Revenues from Enzyme Therapies Portfolio Increased 27% Y/Y
Th...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2024
BMRN
LISTED
NASDAQ
BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET
News Preview
SAN RAFAEL, Calif., Oct. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 29, 2024, at 4:30 p.m. ET to discuss third quarter 2024 financial results and provide a general business...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2024
BMRN
LISTED
NASDAQ
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
News Preview
Results from Ongoing CANOPY Clinical Program for VOXZOGO Showcase Impact of C-Type Natriuretic Peptide (CNP) as Master Regulator of Growth-Related Development Across Multiple Genetic Skeletal Conditions
New Data Highlight Meaningful Improvements in Health-Related Quality of Life for Children with Achondroplasia
Investigator-Led Study Shows Signi...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
BMRN
LISTED
NASDAQ
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
News Preview
NEW YORK, Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Alexander Hardy and other members of BioMarin's leadership team provided an overview of the company's new corporate strategy to deliver sustained value creation and introduced longer...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
BMRN
LISTED
NASDAQ
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
News Preview
NEW YORK, Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host its Investor Day today in New York. The event begins at 10:30 a.m. Eastern Time and can be accessed virtually here.
Led by President an...
Themefolio
Profiler
Peergroup
© PR Newswire
29.08.2024
BMRN
LISTED
NASDAQ
BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
News Preview
SAN RAFAEL, Calif., Aug. 29, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5, 2024, at 7:45 AM PT / 10:45 AM ET in New York, NY....
Themefolio
Profiler
Peergroup
© PR Newswire
21.08.2024
BMRN
LISTED
NASDAQ
BioMarin Announces New R&D and Business Development Leadership
News Preview
Greg Friberg, M.D., Appointed EVP, Chief Research & Development Officer as Hank Fuchs, M.D., Will Retire After 15 Years at Company
James Sabry, M.D., Ph.D., Appointed EVP, Chief Business Officer
SAN RAFAEL, Calif., Aug. 21, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the appointments of Greg Friberg, M.D.,...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2024
BMRN
LISTED
NASDAQ
BioMarin to Host 2024 Investor Day on September 4th in New York
News Preview
-Event to be webcast live and a replay will be available
SAN RAFAEL, Calif., Aug. 19, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an Investor Day with financial analysts and institutional investors on Wednesday, September 4, 2024, in New York City from 10:30 am to 1:00 pm Eastern Time. The event will feature prese...
Themefolio
Profiler
Peergroup
© Newsfile
04.02.2022
BMRN
LISTED
NASDAQ
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
News Preview
Wilmington, Delaware--(Newsfile Corp. - February 3, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) on behalf of stockholders.On October 25, 2021, a class action complaint was filed against BioMarin. The complaint alleges that, between Janu...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
